PEPTORYN / RESEARCH SERIES

Peptoryn Retatrutide, 5 mg research product vial

Product visualization

Metabolic research

Retatrutide

Research focusWeight loss & appetite

€57.00Currently unavailable

Laboratory research only · Not for human use

Select size 5 mg

Out of stock

5 mg · Single vial

Compound profile

RESEARCH AT A GLANCE

Retatrutide, made clearer.

Learn

Research topicWeight loss & appetite

EvidenceHuman studies

In our library2 linked studies

Research areas describe what is studied. They do not promise a benefit.

What researchers study

A GIP, GLP-1, and glucagon receptor agonist evaluated in the linked phase 2 obesity trial.

CompoundIdentity matters

Study modelMetabolic physiology

ObservationA measured outcome

Combines activity at three hormone receptors. The linked 2023 trial provides human evidence, not a personal-use protocol.

Conceptual study process

Evidence & sources

Some research involves people. Study population, measured outcomes, and trial conditions determine what the findings mean.

CURATED LIBRARY

Linked study types

2 linked studies

Library counts only. This is not an effectiveness score or a complete research review.

Human randomized trial2023

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

This placebo-controlled phase 2 trial followed 338 adults for 48 weeks. The investigational receptor agonist produced weight reduction across treatment groups; gastrointestinal events and increases in heart rate were reported.

Study limitations

A phase 2 result does not establish long-term safety, outcomes in excluded groups, or regulatory approval. This record describes the 2023 publication, not a current regulatory-status assessment.

Study notes Original publication

Human randomized trial2022

LY3437943, a triple receptor agonist: a phase 1b trial in people with type 2 diabetes

A 12-week phase 1b study enrolled 72 adults with type 2 diabetes. The authors reported an approximate six-day half-life for LY3437943 (retatrutide). Gastrointestinal events were common. This historical trial supports the half-life teaching example, not a personal regimen.

Study limitations

Small early-phase population, short follow-up and substantial discontinuation limit generalization. A population pharmacokinetic estimate is not an individual blood-level prediction, a safe washout interval, or evidence that a research vial matches the trial formulation.

Study notes Original publication

Profile referencesfda.gov Reference 1

Limitations & safety

This listing does not establish human safety or treatment benefit.

Clinical benefit and long-term safety are not established by the evidence curated here.
Identity, purity, formulation, and route affect risk; a research label is not evidence of suitability for human use.

Explore the half-life chart

SEE THE CONCEPT

Half-life, visualized.

Interactive model

Each half-life halves the starting quantity.

50%modeled quantity remaining

1 half-life elapsed6 example days

Remaining fraction = (½)^{elapsed half-lives}

Illustrative model, not a dosing schedule.

Model details & study source

A 2022 phase 1b Retatrutide study reported an approximate six-day half-life. This is a normalized, single-elimination teaching model, not measured blood levels, a clearance guarantee, an efficacy curve or a dosing schedule. Absorption and individual pharmacokinetics are not modeled. Read the original study

Full profile Evidence tiers Storage guide

Product details

A GIP, GLP-1, and glucagon receptor agonist evaluated in the linked phase 2 obesity trial.

Check batch documentation and laboratory characterization for the supplied product. Published research does not validate this vial’s quality, safety or efficacy.

SKU: PYN-RETATRUTIDE-5MG5 mg · Single vial

Shipping & orders

Shipping costs and payment options appear at checkout. Follow the instructions saved with your order; our team verifies payment before shipping. Tracking updates appear in your account.

Your orders